Fig. 1 | Scientific Reports

Fig. 1

From: The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study

Fig. 1

Kaplan–Meier analysis of overall survival. (A) All patients’ Kaplan–Meier analysis of overall survival (OS) are shown, according to modified response evaluation criteria in solid tumors. Median OS is 13.0 months (95% CI 10.587–15.413). (B) Kaplan–Meier estimates of OS among experimental group and control group are shown. P-value calculated is < 0.05.

Back to article page